
  
    
      
        Introduction_NNP
        Systemic_NNP sclerosis_NN (_( SSc_NNP )_) is_VBZ a_DT connective-tissue_JJ disease_NN
        characterized_VBN by_IN progressive_JJ thickening_VBG of_IN the_DT dermis_NNS ,_,
        often_RB accompanied_VBN by_IN insufficiency_NN of_IN internal_JJ organs_NNS ,_, such_JJ
        as_IN the_DT lungs_NNS ,_, heart_NN ,_, or_CC kidneys_NNS [_NN 1_CD ]_NN ._. These_DT manifestations_NNS
        are_VBP due_JJ to_TO the_DT excessive_JJ accumulation_NN of_IN extracellular_NN
        matrix_NN proteins_NNS ,_, predominantly_RB type_NN I_PRP collagen_NN ,_, in_IN the_DT
        affected_VBN tissues_NNS [_NN 2_CD ]_NN ._. The_DT cause_NN of_IN SSc_NNP is_VBZ unknown_JJ but_CC the_DT
        early_JJ stage_NN is_VBZ characterized_VBN by_IN a_DT dense_JJ mononuclear_NN cell_NN
        infiltrate_VB in_IN tissues_NNS ,_, suggesting_VBG that_DT activation_NN of_IN the_DT
        immune_JJ system_NN results_NNS in_IN the_DT development_NN of_IN tissue_NN fibrosis_NNS
        [_NN 3_CD ,_, 4_CD ]_NN ._. A_DT prominent_JJ humoral_NN abnormality_NN in_IN SSc_NNP is_VBZ
        manifested_JJ by_IN the_DT presence_NN of_IN anti-nuclear_JJ antibodies_NNS [_NN 5_CD ]_NN ._.
        The_DT circulating_VBG anti-topoisomerase-_JJ I_PRP (_( anti-_NN Topo_NNP I_PRP ;_: Scl-_NNP 70_CD )_)
        antibodies_NNS are_VBP highly_RB specific_JJ for_IN SSc_NNP [_NN 6_CD ]_NN ,_, and_CC they_PRP are_VBP
        found_VBN in_IN sera_NN from_IN 30_CD to_TO 70_CD %_NN of_IN patients_NNS [_NN 7_CD ]_NN ._. The_DT presence_NN
        of_IN anti-_NN Topo-_NNP I_PRP antibodies_NNS is_VBZ associated_VBN with_IN diffuse_NN
        cutaneous_JJ involvement_NN and_CC pulmonary_JJ interstitial_NN fibrosis_NNS [_NN
        8_CD ]_NN and_CC is_VBZ considered_VBN a_DT predictive_JJ marker_NN of_IN diffuse_NN
        SSc_NNP ._.
        Human_NNP DNA_NNP topoisomerase_NN I_PRP (_( Topo_NNP I_PRP )_) is_VBZ a_DT 765_CD -_: amino-acid_JJ
        nuclear_JJ enzyme_NN [_NN 9_CD ]_NN involved_VBN in_IN topological_JJ changes_NNS of_IN DNA_NNP
        structure_NN [_NN 10_CD ]_NN ._. It_PRP plays_VBZ key_JJ roles_NNS in_IN DNA_NNP replication_NN ,_,
        transcription_NN ,_, and_CC recombination_NN ._. During_IN the_DT Topo_NNP I_PRP
        catalytic_JJ process_NN ,_, a_DT transient_JJ covalent_NN linkage_NN ,_, termed_VBD the_NNP
        '_POS cleavable_JJ complex_JJ '_POS ,_, is_VBZ formed_VBN between_IN the_DT enzyme_NN and_CC DNA_NNP
        strand_NN nicks_NNS ._. Camptothecin_NNP (_( CPT_NNP )_) and_CC its_PRP$ derivatives_NNS
        specifically_RB target_VBP Topo_NNP I_PRP by_IN binding_JJ noncovalently_RB to_TO
        these_DT cleavable_JJ complexes_NNS ,_, stabilizing_VBG them_PRP and_CC interfering_VBG
        with_IN DNA_NNP religation_NN [_NN 11_CD ]_NN ._. As_IN a_DT result_NN of_IN CPT_NNP 's_POS action_NN ,_,
        single-_NN and_CC double-strand_JJ DNA_NNP breaks_NNS are_VBP generated_VBN ,_, leading_VBG
        to_TO premature_JJ termination_NN of_IN replication_NN and_CC inhibition_NN of_IN
        transcription_NN [_NN 12_CD ]_NN ._. Cells_NNP can_MD repair_VB DNA_NNP breaks_NNS caused_VBN by_IN
        low_JJ doses_NNS of_IN CPT_NNP ,_, whereas_IN higher_JJR doses_NNS lead_VBP to_TO cell_NN death_NN [_NN
        13_CD ]_NN ._. Since_IN many_JJ neoplastic_JJ cells_NNS are_VBP characterized_VBN by_IN high_JJ
        levels_NNS and_CC /_NN or_CC activities_NNS of_IN Topo_NNP I_PRP [_NN 14_CD ,_, 15_CD ]_NN ,_, this_DT enzyme_NN
        has_VBZ become_VBN one_CD of_IN the_DT cellular_JJ targets_NNS for_IN anticancer_NN
        therapy_NN [_NN 16_CD ,_, 17_CD ]_NN ._. CPT_NNP derivatives_NNS such_JJ as_IN topotecan_NN and_CC
        irinotecan_NN (_( CPT-_NNP 11_CD )_) are_VBP currently_RB used_VBN in_IN the_DT treatment_NN of_IN
        various_JJ cancers_NNS [_NN 16_CD ,_, 17_CD ,_, 18_CD ]_NN ._. Only_RB limited_JJ side_NN effects_NNS ,_,
        such_JJ as_IN manageable_JJ neutropenia_NN ,_, in_IN patients_NNS who_WP received_VBD
        high_JJ doses_NNS of_IN Topo_NNP I_PRP inhibitors_NNS have_VBP been_VBN reported_VBN [_NN 16_CD ,_,
        17_CD ]_NN ._.
        The_DT mechanism_NN responsible_JJ for_IN the_DT production_NN of_IN
        anti-_NN Topo-_NNP I_PRP antibodies_NNS in_IN SSc_NNP is_VBZ not_RB fully_RB understood_VBN ._.
        Recent_JJ studies_NNS suggest_VBP that_DT activation_NN of_IN Topo-_NNP I-_NNP reactive_JJ T_NN
        cells_NNS is_VBZ responsible_JJ for_IN the_DT induction_NN and_CC propagation_NN of_IN
        these_DT antibodies_NNS in_IN SSc_NNP patients_NNS [_NN 19_CD ]_NN ._. At_IN present_JJ ,_, the_DT
        origin_NN of_IN their_PRP$ target_NN autoantigen_NN is_VBZ not_RB clear_JJ ._.
        Significantly_RB ,_, the_DT disappearance_NN of_IN these_DT antibodies_NNS ,_,
        possibly_RB because_IN of_IN removal_NN of_IN the_DT autoantigen_NN ,_, has_VBZ been_VBN
        associated_VBN with_IN favorable_JJ outcomes_NNS [_NN 20_CD ]_NN ._. Because_IN of_IN the_DT
        potential_JJ pathogenic_JJ role_NN of_IN Topo_NNP I_PRP in_IN SSc_NNP ,_, we_PRP undertook_VBD
        this_DT study_NN to_TO evaluate_VB the_DT utility_NN of_IN noncytotoxic_JJ
        concentrations_NNS of_IN Topo_NNP I_PRP inhibitors_NNS for_IN the_DT treatment_NN of_IN
        SSc_NNP ._. We_PRP have_VBP focused_VBN on_IN the_DT effects_NNS of_IN the_DT leading_VBG Topo_NNP I_PRP
        inhibitor_NN ,_, CPT_NNP ,_, on_IN collagen_NN production_NN by_IN dermal_NN
        fibroblasts_NNS obtained_VBN from_IN patients_NNS with_IN SSc_NNP ._.
      
      
        Patients_NNS and_CC methods_NNS
        
          Patients_NNS
          The_DT subjects_NNS were_VBD patients_NNS with_IN diffuse_NN SSc_NNP and_CC
          healthy_JJ volunteers_NNS ._. The_DT patient_NN group_NN consisted_VBD of_IN 18_CD
          individuals_NNS (_( 10_CD women_NNS and_CC 8_CD men_NNS )_) with_IN a_DT mean_JJ age_NN of_IN 39_CD ._. 5_LS
          ±_NN 2_CD ._. 6_CD years_NNS ._. All_DT the_DT patients_NNS fulfilled_VBD the_DT American_NNP
          College_NNP of_IN Rheumatology_NNP criteria_NNS for_IN the_DT diagnosis_NN of_IN SSc_NNP
          [_NN 21_CD ]_NN ._. The_DT control_NN group_NN were_VBD 18_CD healthy_JJ donors_NNS with_IN a_DT
          mean_JJ age_NN of_IN 41_CD ._. 0_CD ±_NN 3_CD ._. 3_CD years_NNS ._.
        
        
          Cell_NNP culture_NN
          Dermal_NNP fibroblasts_NNS were_VBD obtained_VBN from_IN clinically_RB
          affected_VBN skin_NN (_( on_IN the_DT dorsal_NN forearm_NN )_) of_IN the_DT SSc_NNP patients_NNS
          and_CC from_IN healthy_JJ donors_NNS matched_VBN with_IN the_DT patients_NNS for_IN
          race_NN ,_, age_NN ,_, and_CC gender_NN ._. The_DT control_NN fibroblasts_NNS were_VBD
          obtained_VBN within_IN several_JJ days_NNS of_IN SSc_NNP biopsy_NN and_CC were_VBD
          processed_VBN in_IN parallel_NN ._. For_IN the_DT experiments_NNS ,_, cells_NNS were_VBD
          starved_VBN for_IN 48_CD h_NN before_IN the_DT addition_NN of_IN CPT_NNP in_IN DMEM_NNP /_NN 1_CD %_NN
          fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) ._.
        
        
          Reagents_NNP
          CPT_NNP was_VBD purchased_VBN from_IN Sigma_NNP (_( St_NNP Louis_NNP ,_, MO_NNP ,_, USA_NNP )_) and_CC
          dissolved_VBN in_IN dimethyl_NN sulfoxide_NN (_( Sigma_NNP )_) ._. Aliquots_NNP of_IN
          stock_NN solution_NN (_( 10_CD mM_NN )_) were_VBD stored_VBN at_IN -_: 70_CD °_NN C_NNP ._.
        
        
          Determination_NNP of_IN collagen_NN types_NNS and_CC of_IN elastin_NN
          production_NN
          Collagen_NNP and_CC elastin_NN deposition_NN in_IN cell_NN and_CC matrix_NN
          layers_NNS was_VBD determined_VBN by_IN solid-phase_JJ ELISA_NNP with_IN
          antibodies_NNS against_IN goat_NN anti-collagen_JJ I_PRP (_( Chemicon_NNP ,_,
          Temecula_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, mouse_NN anti-collagen_JJ III_NNP (_( Telios_NNP ,_, San_NNP
          Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, mouse_NN anti-collagen_JJ VI_NNP (_( Telios_NNP )_) ,_, or_CC
          mouse_NN anti-elastin_JJ (_( Sigma_NNP )_) ,_, at_IN dilutions_NNS recommended_VBN by_IN
          the_DT manufacturers_NNS ._.
          To_TO determine_VB the_DT effect_NN of_IN CPT_NNP on_IN newly_RB synthesized_JJ
          collagenous_JJ proteins_NNS ,_, we_PRP used_VBD an_DT established_VBN method_NN of_IN
          metabolic_JJ labeling_VBG with_IN [_NN 3_CD H_NNP ]_NN proline_NN followed_VBN by_IN SDS-PAGE_NNP
          electrophoresis_NNS [_NN 22_CD ]_NN ._. The_DT results_NNS were_VBD visualized_JJ by_IN
          autoradiography_NN ._. The_DT intensity_NN of_IN bands_NNS of_IN collagenous_JJ
          protein_NN was_VBD quantitated_JJ using_VBG NIH-Image_NNP (_( Densitometry_NNP
          Software_NNP ,_, version_NN 1_CD ._. 55_CD )_) ._. The_DT effect_NN of_IN CPT_NNP on_IN total_JJ
          protein_NN synthesis_NN was_VBD examined_VBN using_VBG metabolic_JJ labeling_VBG
          with_IN [_NN 35_CD S_NNP ]_NN methionine_NN followed_VBN by_IN SDS-PAGE_NNP and_CC
          autoradiography_NN ._.
        
        
          RNA_NNP preparation_NN and_CC northern_JJ blot_NN analysis_NN
          Fibroblasts_NNP were_VBD treated_VBN with_IN CPT_NNP at_IN concentrations_NNS
          from_IN 10_CD -_: 9_CD to_TO 10_CD -_: 6_CD mol_NN /_NN l_NN for_IN 24_CD h_NN ._. Total_NNP RNA_NNP was_VBD extracted_VBN
          and_CC analyzed_VBN by_IN northern_JJ blotting_VBG as_IN described_VBN elsewhere_RB
          [_NN 23_CD ]_NN ._. Membranes_NNP were_VBD sequentially_RB hybridized_JJ with_IN
          radioactive_JJ probes_NNS for_IN α_NN 2_CD (_( I_NN )_) procollagen_NN and_CC
          glyceraldehyde-_NN 3_CD -_: phosphate_NN dehydrogenase_NN (_( GAPDH_NNP )_) and_CC
          scanned_JJ with_IN a_DT PhosphorImager_NNP (_( Molecular_NNP Dynamics_NNP ,_, Inc_NNP ,_,
          Sunnyvale_NNP ,_, CA_NNP )_) for_IN mRNA_NN quantitation_NN ._.
        
        
          Transient_NNP transfection_NN and_CC chloramphenicol_NN
          acetyltransferase_NN assays_NNS
          Transient_NNP transfections_NNS of_IN normal_JJ dermal_NN fibroblasts_NNS
          were_VBD performed_VBN with_IN 20_CD μg_NN of_IN the_DT -_: 353_CD fragment_NN of_IN α_NN 2_CD (_( I_NN )_)
          collagen_NN (_( COL_NNP 1_CD A_DT 2_LS )_) promoter_NN linked_VBN to_TO the_DT chloramphenicol_NN
          acetyltransferase_NN (_( CAT_NNP )_) reporter_NN gene_NN by_IN the_DT calcium_NN
          phosphate_NN /_NN DNA_NNP coprecipitation_NN technique_NN as_IN described_VBN
          elsewhere_RB [_NN 24_CD ]_NN ._. CAT_NNP values_NNS were_VBD corrected_VBN to_TO reflect_VB the_DT
          efficiency_NN of_IN transfection_NN relative_JJ to_TO the_DT co-transfected_JJ
          pSV-β-galactosidase_JJ vector_NN (_( Promega_NNP ,_, Madison_NNP ,_, WI_NNP ,_,
          USA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP signifance_NN was_VBD evaluated_VBN in_IN paired_VBN
          analyses_NNS using_VBG the_DT Student_NNP 's_POS paired_VBN 
          t_NN test_NN or_CC the_DT Wilcoxon_NNP test_NN
          (_( nonparametric_JJ )_) ,_, depending_VBG on_IN the_DT data_NNS distribution_NN ._. Data_NNP
          values_NNS are_VBP expressed_VBN as_IN means_VBZ ±_NN SEM_NNP ._. Statistical_NNP
          significance_NN was_VBD defined_VBN as_IN a_DT 
          P_NN value_NN of_IN 0_CD ._. 05_CD or_CC less_JJR (_( see_VB
          supplementary_JJ material_NN )_) ._.
        
      
      
        Results_NNS
        
          Effect_NN of_IN CPT_NNP on_IN production_NN of_IN collagen_NN
          protein_NN
          The_DT effect_NN of_IN CPT_NNP on_IN the_DT production_NN of_IN types_NNS I_PRP ,_, III_NNP ,_,
          and_CC VI_NNP collagen_NN by_IN 11_CD pairs_NNS of_IN SSc_NNP and_CC normal_JJ dermal_NN
          fibroblasts_NNS was_VBD examined_VBN by_IN ELISA_NNP using_VBG fibroblast_NN cell_NN
          and_CC matrix_NN layers_NNS (_( Fig_NNP ._. 1_LS a_DT ,_, b_SYM ,_, c_SYM )_) ._. Incubation_NNP with_IN CPT_NNP for_IN
          24_CD h_NN significantly_RB decreased_VBD the_DT expression_NN of_IN all_DT three_CD
          collagen_NN types_NNS ,_, although_IN the_DT degree_NN of_IN inhibition_NN varied_VBD
          among_IN the_DT different_JJ collagens_NNS ._. Although_IN CPT_NNP at_IN 10_CD -_: 7_CD mol_NN /_NN l_NN
          decreased_VBD collagen_NN production_NN more_JJR in_IN SSc_NNP than_IN in_IN healthy_JJ
          control_NN fibroblasts_NNS (_( by_IN ,_, respectively_RB ,_, 68_CD %_NN and_CC 48_CD %_NN for_IN
          type_NN I_PRP ,_, 38_CD %_NN and_CC 15_CD %_NN for_IN type_NN II_NNP ,_, and_CC 21_CD %_NN and_CC 7_CD %_NN for_IN type_NN
          III_NNP )_) (_( Fig_NNP ._. a_DT ,_, b_SYM ,_, c_SYM )_) ,_, these_DT differences_NNS were_VBD not_RB
          statistically_RB significant_JJ ._. The_DT reduction_NN of_IN type_NN I_PRP
          collagen_NN expression_NN by_IN CPT_NNP after_IN 24_CD h_NN was_VBD also_RB
          demonstrated_VBN by_IN immunocytochemistry_NN and_CC indirect_JJ
          immunofluorescence_NN (_( data_NNS not_RB shown_VBN )_) ._. To_TO assess_VB the_DT effect_NN
          of_IN CPT_NNP on_IN production_NN of_IN other_JJ extracellular_NN matrix_NN
          proteins_NNS ,_, the_DT effect_NN on_IN elastin_NN was_VBD measured_VBN by_IN ELISA_NNP :_: no_DT
          effect_NN was_VBD found_VBN in_IN either_DT SSc_NNP or_CC control_NN fibroblasts_NNS
          (_( Fig_NNP ._. 1_LS d_SYM )_) ._.
          The_DT effect_NN of_IN CPT_NNP on_IN newly_RB synthesized_JJ collagenous_JJ
          proteins_NNS secreted_JJ into_IN the_DT media_NNS was_VBD examined_VBN in_IN five_CD
          pairs_NNS of_IN SSc_NNP and_CC healthy_JJ control_NN fibroblasts_NNS in_IN nine_CD
          independent_JJ experiments_NNS ._. CPT_NNP at_IN concentrations_NNS from_IN 10_CD
          -_: 8_CD to_TO 10_CD -_: 6_CD mol_NN /_NN l_NN significantly_RB decreased_VBD secretion_NN of_IN
          collagenous_JJ protein_NN ,_, by_IN up_IN to_TO 50_CD %_NN in_IN both_DT cell_NN types_NNS
          (_( Fig_NNP ._. 2_LS a_DT ,_, b_SYM )_) ._. The_DT responsiveness_NNS of_IN SSc_NNP and_CC healthy_JJ
          control_NN fibroblasts_NNS to_TO different_JJ doses_NNS of_IN CPT_NNP was_VBD also_RB
          compared_VBN ._. No_DT major_JJ differences_NNS were_VBD observed_VBN at_IN the_DT three_CD
          highest_JJS doses_NNS used_VBN (_( 10_CD -_: 8_CD to_TO 10_CD -_: 6_CD mol_NN /_NN l_NN )_) ,_, but_CC SSc_NNP
          fibroblasts_NNS appeared_VBD to_TO be_VB slightly_RB more_RBR sensitive_JJ to_TO the_DT
          lowest_JJS dose_NN of_IN CPT_NNP (_( 10_CD -_: 9_CD mol_NN /_NN l_NN )_) ._. Secreted_NNP collagenous_JJ
          proteins_NNS were_VBD inhibited_VBD by_IN 29_CD %_NN ±_NN 0_CD ._. 06_CD in_IN SSc_NNP fibroblasts_NNS
          versus_CC 14_CD %_NN ±_NN 0_CD ._. 03_CD in_IN healthy_JJ control_NN fibroblasts_NNS (_( 
          P_NN =_SYM 0_CD ._. 09_CD )_) ._. The_DT total_JJ protein_NN
          synthesis_NN was_VBD not_RB affected_VBN by_IN CPT_NNP treatment_NN ,_, even_RB at_IN the_DT
          highest_JJS dose_NN used_VBN (_( 10_CD -_: 6_CD mol_NN /_NN l_NN )_) (_( Fig_NNP ._. 2_LS c_SYM )_) ._. The_DT number_NN of_IN
          cells_NNS after_IN CPT_NNP treatment_NN was_VBD not_RB significantly_RB decreased_VBD
          (_( Table_NNP 1_LS )_) ,_, indicating_VBG that_IN the_DT doses_NNS used_VBN were_VBD not_RB
          cytotoxic_JJ to_TO fibroblasts_NNS ._. CPT_NNP is_VBZ cytotoxic_JJ mainly_RB to_TO
          S-_NNP phase_NN cells_NNS ,_, and_CC its_PRP$ effects_NNS are_VBP dependent_JJ on_IN cell_NN type_NN
          [_NN 13_CD ]_NN ._. In_IN general_JJ ,_, human_JJ fibroblasts_NNS are_VBP more_RBR resistant_JJ
          than_IN neoplastic_JJ cells_NNS or_CC lymphoblasts_NNS to_TO DNA-damaging_NNP
          agents_NNS [_NN 25_CD ]_NN ._. Although_IN it_PRP has_VBZ been_VBN shown_VBN that_IN CPT_NNP at_IN
          higher_JJR concentrations_NNS induces_VBZ cell_NN cycle_NN arrest_NN in_IN
          proliferating_VBG dermal_NN fibroblasts_NNS [_NN 26_CD ]_NN ,_, it_PRP is_VBZ unlikely_JJ
          that_IN the_DT inhibition_NN of_IN collagen_NN production_NN was_VBD related_VBN to_TO
          cell_NN cycle_NN arrest_NN ,_, because_IN our_PRP$ experiments_NNS were_VBD performed_VBN
          with_IN confluent_NN ,_, serum-starved_JJ cells_NNS ._. Taken_VBN together_RB ,_, the_DT
          experiments_NNS presented_VBN in_IN this_DT part_NN of_IN the_DT study_NN suggest_VBP
          that_IN CPT_NNP is_VBZ a_DT relatively_RB specific_JJ inhibitor_NN of_IN
          collagenous_JJ protein_NN production_NN in_IN dermal_NN fibroblasts_NNS ._.
        
        
          Effect_NN of_IN CPT_NNP on_IN expression_NN of_IN COL_NNP 1_CD A_DT 2_CD mRNA_NN
          The_DT effect_NN of_IN CPT_NNP on_IN COL_NNP 1_CD A_DT 2_CD steady-state_JJ mRNA_NN levels_NNS
          was_VBD evaluated_VBN in_IN seven_CD pairs_NNS of_IN SSc_NNP and_CC healthy_JJ control_NN
          dermal_NN fibroblasts_NNS in_IN 13_CD independent_JJ experiments_NNS ._. CPT_NNP
          treatment_NN resulted_VBD in_IN a_DT dose-dependent_JJ decrease_NN of_IN COL_NNP 1_CD A_DT 2_CD
          mRNA_NN expression_NN levels_NNS in_IN SSc_NNP and_CC healthy_JJ control_NN
          fibroblasts_NNS as_IN demonstrated_VBN by_IN northern_JJ blot_NN analysis_NN ._.
          Note_VB that_IN GAPDH_NNP mRNA_NN levels_NNS were_VBD not_RB inhibited_VBD by_IN CPT_NNP
          (_( Fig_NNP ._. 3_LS a_DT )_) ._. The_DT highest_JJS dose_NN of_IN CPT_NNP (_( 10_CD -_: 6_CD )_) resulted_VBD in_IN
          about_IN 60_CD %_NN inhibition_NN of_IN COL_NNP 1_CD A_DT 2_CD mRNA_NN levels_NNS in_IN both_DT SSc_NNP
          and_CC healthy_JJ control_NN fibroblasts_NNS (_( Fig_NNP ._. 3_LS b_SYM ,_, c_SYM )_) ._. These_DT
          results_NNS suggest_VBP that_IN the_DT inhibitory_NN effects_NNS of_IN CPT_NNP occur_VB ,_,
          at_IN least_JJS partially_RB ,_, through_IN regulating_VBG the_DT levels_NNS of_IN
          expression_NN of_IN collagen_NN mRNA_NN ._.
        
        
          Effect_NN of_IN CPT_NNP on_IN activity_NN of_IN COL_NNP 1_CD A_DT 2_CD promoter_NN
          The_DT transcriptional_NN activity_NN of_IN the_DT human_JJ COL_NNP 1_CD A_DT 2_CD
          promoter_NN fragment_NN (_( -_: 353_CD )_) linked_VBN to_TO the_DT CAT_NNP reporter_NN gene_NN
          was_VBD examined_VBN in_IN transient_JJ transfection_NN assays_NNS after_IN CPT_NNP
          treatment_NN ._. Consistent_NNP with_IN the_DT mRNA_NN data_NN ,_, the_DT maximal_NN
          inhibition_NN of_IN collagen_NN promoter_NN activity_NN was_VBD 60_CD %_NN (_( Fig_NNP ._.
          4_LS )_) ,_, suggesting_VBG that_IN the_DT inhibitory_NN effect_NN of_IN CPT_NNP on_IN the_DT
          COL_NNP 1_CD A_DT 2_CD gene_NN occurs_VBZ at_IN the_DT transcriptional_NN level_NN ._. As_IN
          previously_RB reported_VBN ,_, CPT_NNP has_VBZ no_DT effect_NN on_IN the_DT activity_NN of_IN
          the_DT control_NN vector_NN [_NN 27_CD ]_NN ._. The_DT activity_NN of_IN the_DT collagen_NN
          promoter_NN was_VBD inhibited_VBD by_IN much_RB lower_JJR doses_NNS of_IN CPT_NNP (_( 10_CD
          -_: 12_CD and_CC 10_CD -_: 10_CD mol_NN /_NN l_NN )_) than_IN those_DT that_WDT inhibited_VBD collagen_NN
          mRNA_NN levels_NNS (_( 10_CD -_: 8_CD to_TO 10_CD -_: 6_CD mol_NN /_NN l_NN )_) ._. This_DT probably_RB reflects_VBZ
          the_DT difference_NN in_IN sensitivity_NN to_TO CPT_NNP between_IN exogenous_JJ
          and_CC endogenous_JJ promoters_NNS due_JJ to_TO the_DT protective_JJ role_NN of_IN
          chromatin_NN surrounding_VBG the_DT endogenous_JJ promoter_NN ._.
        
      
      
        Discussion_NNP
        DNA_NNP Topo_NNP I_PRP is_VBZ an_DT essential_JJ enzyme_NN involved_VBN in_IN such_JJ
        crucial_JJ cellular_JJ functions_NNS as_IN replication_NN and_CC
        transcription_NN ._. This_DT study_NN was_VBD undertaken_VBN to_TO determine_VB
        whether_IN inhibition_NN of_IN its_PRP$ activity_NN by_IN noncytotoxic_JJ doses_NNS of_IN
        CPT_NNP ,_, a_DT drug_NN that_IN selectively_RB targets_VBZ Topo_NNP I_PRP ,_, could_MD reverse_VB
        the_DT activated_VBN phenotype_NN of_IN fibroblasts_NNS from_IN patients_NNS with_IN
        SSc_NNP ._. CPT_NNP ,_, an_DT alkaloid_NN that_WDT exists_VBZ in_IN nature_NN and_CC has_VBZ been_VBN
        used_VBN for_IN centuries_NNS in_IN traditional_JJ Chinese_JJ medicine_NN ,_, is_VBZ a_DT
        prototype_NN of_IN a_DT new_JJ class_NN of_IN anticancer_NN drugs_NNS [_NN 16_CD ]_NN ._. It_PRP is_VBZ
        commonly_RB used_VBN in_IN 
        in_IN vitro_NN experimental_JJ model_NN systems_NNS
        to_TO study_VB the_DT mechanisms_NNS of_IN action_NN of_IN Topo_NNP I_PRP inhibitors_NNS ._.
        Clinically_NNP approved_VBD Topo_NNP I_PRP inhibitors_NNS ,_, irinotecan_NN and_CC
        topotecan_NN ,_, are_VBP semisynthetic_JJ derivatives_NNS of_IN CPT_NNP that_WDT differ_VBP
        from_IN CPT_NNP in_IN toxicity_NN profiles_NNS and_CC water_NN solubility_NN but_CC not_RB
        in_IN the_DT mechanisms_NNS of_IN action_NN [_NN 16_CD ,_, 17_CD ]_NN ._.
        Our_PRP$ results_NNS show_VBP that_IN CPT_NNP significantly_RB inhibits_NNS the_DT
        synthesis_NN of_IN collagen_NN by_IN dermal_NN fibroblasts_NNS from_IN patients_NNS
        with_IN SSc_NNP ._. The_DT production_NN of_IN types_NNS I_PRP ,_, III_NNP ,_, and_CC VI_NNP collagen_NN
        was_VBD significantly_RB inhibited_VBD in_IN SSc_NNP and_CC healthy_JJ control_NN
        dermal_NN fibroblasts_NNS without_IN affecting_VBG total_JJ protein_NN
        synthesis_NN ._. The_DT inhibitory_NN mechanism_NN of_IN CPT_NNP was_VBD further_RBR
        examined_VBD using_VBG COL_NNP 1_CD A_DT 2_CD as_IN a_DT representative_NN collagen_NN gene_NN ._.
        The_DT drug_NN inhibited_VBD COL_NNP 1_CD A_DT 2_CD steady-state_JJ mRNA_NN levels_NNS and_CC
        promoter_NN activity_NN by_IN 60_CD %_NN ,_, indicating_VBG that_IN it_PRP directly_RB
        inhibits_NNS transcription_NN of_IN this_DT collagen_NN gene_NN ._. It_PRP is_VBZ not_RB
        known_VBN why_WRB collagen_NN genes_NNS ,_, and_CC particularly_RB type_NN I_PRP collagen_NN ,_,
        are_VBP more_RBR sensitive_JJ to_TO CPT_NNP than_IN other_JJ genes_NNS ._. The_DT drug_NN either_CC
        may_MD directly_RB interfere_VB with_IN the_DT transcription_NN of_IN collagen_NN
        genes_NNS or_CC may_MD influence_VB signaling_VBG pathways_NNS that_WDT regulate_VB
        collagen_NN gene_NN expression_NN ._.
        The_DT role_NN of_IN Topo_NNP I_PRP in_IN the_DT initiation_NN of_IN transcription_NN
        has_VBZ previously_RB been_VBN shown_VBN [_NN 28_CD ]_NN ._. These_DT previous_JJ studies_NNS
        have_VBP revealed_VBN that_IN Topo_NNP I_PRP can_MD act_VB as_IN either_DT an_DT activator_NN or_CC
        a_DT repressor_NN ,_, depending_VBG on_IN the_DT promoter_NN and_CC the_DT presence_NN of_IN
        other_JJ transcription_NN factors_NNS [_NN 29_CD ]_NN ._. It_PRP has_VBZ been_VBN proposed_VBN
        that_IN Topo_NNP I_PRP may_MD be_VB directly_RB involved_VBN in_IN transcription_NN of_IN
        interstitial_NN collagen_NN genes_NNS [_NN 30_CD ]_NN ._. The_DT nucleotide_NN sequences_NNS
        of_IN these_DT genes_NNS contain_VBP specific_JJ DNA_NNP motifs_NNS that_WDT constitute_VBP
        high-affinity_JJ Topo_NNP I_PRP binding_JJ sites_NNS [_NN 31_CD ]_NN ._. Three_CD such_JJ DNA_NNP
        motifs_NNS reside_VB within_IN the_DT COL_NNP 1_CD A_DT 2_CD promoter_NN [_NN 30_CD ]_NN ._. Further_RB
        studies_VBZ are_VBP needed_VBN to_TO determine_VB whether_IN Topo_NNP I_PRP plays_VBZ a_DT
        direct_JJ role_NN in_IN the_DT regulation_NN of_IN type_NN I_PRP collagen_NN
        transcription_NN ._.
        Recently_RB ,_, a_DT new_JJ role_NN for_IN CPT_NNP has_VBZ been_VBN proposed_VBN [_NN 32_CD ]_NN ._. It_PRP
        has_VBZ been_VBN shown_VBN to_TO activate_VBP transcription_NN factor_NN NF-κB_NNP in_IN
        various_JJ cell_NN types_NNS ,_, including_VBG a_DT fibroblastic_JJ cell_NN line_NN ._. The_DT
        activation_NN of_IN NF-κB_NNP by_IN CPT_NNP involves_VBZ degradation_NN of_IN the_DT
        cytoplasmic_JJ IκBα_NNP by_IN the_DT ubiquitin-proteasome_JJ pathway_NN ._.
        Topotecan_NNP ,_, a_DT clinically_RB approved_VBN derivative_NN of_IN CPT_NNP ,_, showed_VBD
        similar_JJ effects_NNS ._. The_DT activation_NN of_IN NF-κB_NNP by_IN CPT_NNP may_MD be_VB
        directly_RB related_VBN to_TO the_DT mechanism_NN of_IN CPT_NNP COL_NNP 1_CD A_DT 2_CD gene_NN
        regulation_NN ._. It_PRP has_VBZ been_VBN shown_VBN that_IN the_DT inhibitory_NN effect_NN of_IN
        TNF-α_NNP on_IN COL_NNP 1_CD A_DT 2_CD gene_NN transcription_NN is_VBZ mediated_JJ via_IN NF-κB_NNP [_NN
        33_CD ]_NN ._. Thus_RB ,_, CPT_NNP may_MD inhibit_VB COL_NNP 1_CD A_DT 2_CD by_IN a_DT mechanism_NN involving_VBG
        activation_NN of_IN NF-κB_NNP ._. This_DT hypothesis_NNS could_MD be_VB tested_VBN using_VBG
        other_JJ DNA_NNP topoisomerase_NN poisons_NNS known_VBN to_TO induce_VB NF-κB_NNP [_NN
        34_CD ]_NN ._.
        Despite_IN significant_JJ progress_NN towards_IN understanding_VBG the_DT
        pathogenesis_NNS of_IN SSc_NNP and_CC other_JJ fibrotic_JJ diseases_NNS ,_, effective_JJ
        treatment_NN is_VBZ still_RB lacking_VBG ._. Specific_JJ compounds_NNS that_WDT have_VBP
        the_DT potential_NN to_TO inhibit_VB collagen_NN production_NN such_JJ as_IN CPT_NNP
        and_CC the_DT recently_RB described_VBN inhibitor_NN of_IN geranylgeranyl_NN
        transferase_NN I_PRP [_NN 35_CD ]_NN may_MD prove_VB to_TO be_VB clinically_RB useful_JJ in_IN
        the_DT treatment_NN of_IN fibrosis_NNS ._.
      
      
        Conclusion_NNP
        In_IN conclusion_NN ,_, our_PRP$ study_NN shows_VBZ that_IN CPT_NNP has_VBZ a_DT potent_JJ
        selective_JJ inhibitory_NN effect_NN on_IN collagen_NN gene_NN expression_NN ;_:
        however_RB ,_, the_DT specific_JJ molecular_JJ mechanisms_NNS of_IN action_NN are_VBP
        presently_RB not_RB known_VBN and_CC will_MD require_VB further_JJ study_NN ._.
        The_DT inhibitory_NN effect_NN of_IN CPT_NNP on_IN collagen_NN gene_NN expression_NN
        suggests_VBZ that_IN Topo_NNP I_PRP inhibitors_NNS may_MD be_VB an_DT effective_JJ
        treatment_NN for_IN limiting_VBG fibrosis_NNS in_IN SSc_NNP patients_NNS ._.
      
      
        Supplementary_NNP methods_NNS
        
          Patients_NNS
          Dermal_NNP fibroblasts_NNS were_VBD obtained_VBN from_IN patients_NNS with_IN
          diffuse_NN SSc_NNP and_CC healthy_JJ volunteers_NNS ._. The_DT patient_NN group_NN
          consisted_VBD of_IN 18_CD individuals_NNS (_( 10_CD females_NNS and_CC 8_CD males_NNS )_) ,_,
          whose_WP$ mean_VB age_NN was_VBD 39_CD ._. 5_LS ±_NN 2_CD ._. 6_CD years_NNS (_( range_NN 30_CD -_: 51_CD )_) ._. All_DT
          patients_NNS fulfilled_VBD the_DT American_NNP College_NNP of_IN Rheumatology_NNP
          (_( formerly_RB American_NNP Rheumatism_NNP Association_NNP )_) criteria_NNS for_IN
          the_DT diagnosis_NN of_IN SSc_NNP [_NN 21_CD ]_NN ._. They_PRP were_VBD recruited_VBN from_IN the_DT
          Department_NNP of_IN Dermatology_NNP ,_, Warsaw_NNP Medical_NNP School_NNP ,_, Warsaw_NNP ,_,
          Poland_NNP ,_, and_CC the_DT Division_NNP of_IN Rheumatology_NNP and_CC Immunology_NNP ,_,
          Medical_NNP University_NNP of_IN South_NNP Carolina_NNP ,_, Charleston_NNP ,_, SC_NNP ,_,
          USA_NNP ._. All_DT the_DT patients_NNS enrolled_VBD in_IN the_DT study_NN had_VBD been_VBN
          recently_RB diagnosed_VBN with_IN SSc_NNP and_CC their_PRP$ disease_NN duration_NN
          was_VBD between_IN 1_CD month_NN and_CC 1_CD year_NN ._. When_WRB the_DT skin_NN biopsy_NN was_VBD
          performed_VBN ,_, patients_NNS were_VBD not_RB receiving_VBG any_DT treatment_NN
          known_VBN to_TO influence_VB collagen_NN synthesis_NN or_CC deposition_NN ._. The_DT
          control_NN group_NN included_VBD 18_CD healthy_JJ donors_NNS with_IN a_DT mean_JJ age_NN
          of_IN 41_CD ._. 0_CD ±_NN 3_CD ._. 3_CD years_NNS (_( range_NN 23_CD -_: 60_CD )_) ._. Informed_NNP consent_NN was_VBD
          obtained_VBN from_IN patients_NNS and_CC healthy_JJ donors_NNS before_IN each_DT
          biopsy_NN was_VBD performed_VBN ._.
        
        
          Cell_NNP culture_NN
          SSc_NNP dermal_NN fibroblast_NN cell_NN lines_NNS were_VBD established_VBN from_IN
          biopsy_NN specimens_NNS obtained_VBN from_IN clinically_RB affected_VBN skin_NN
          (_( on_IN the_DT dorsal_NN forearm_NN )_) ._. Control_NN dermal_NN fibroblasts_NNS ,_, from_IN
          healthy_JJ donors_NNS matched_VBN for_IN race_NN ,_, age_NN ,_, and_CC gender_NN with_IN
          donors_NNS of_IN SSc_NNP cell_NN lines_NNS ,_, were_VBD obtained_VBN by_IN skin_NN biopsy_NN
          within_IN several_JJ days_NNS of_IN the_DT SSc_NNP biopsy_NN and_CC were_VBD processed_VBN
          in_IN parallel_NN ._. Each_DT biopsy_NN was_VBD dissociated_JJ enzymatically_RB by_IN
          0_CD ._. 25_CD %_NN collagenase_NN type_NN I_PRP (_( Sigma_NNP )_) and_CC 0_CD ._. 05_CD %_NN DNase_NNP (_( Sigma_NNP )_)
          in_IN DMEM_NNP with_IN 20_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) (_( HyClone_NNP )_) ._. The_DT
          fibroblasts_NNS were_VBD cultured_JJ in_IN DMEM_NNP containing_VBG 10_CD %_NN FBS_NNP and_CC
          50_CD μg_NN /_NN ml_NN gentamicin_NN (_( Sigma_NNP )_) ._. For_IN experiments_NNS ,_, cells_NNS were_VBD
          starved_VBN in_IN serum-free-medium_JJ (_( 0_CD ._. 1_LS %_NN BSA_NNP in_IN DMEM_NNP )_) for_IN 48_CD h_NN
          before_IN the_DT addition_NN of_IN CPT_NNP (_( Sigma_NNP )_) in_IN DMEM_NNP /_NN 1_CD %_NN FBS_NNP ._. The_DT
          fibroblasts_NNS used_VBN for_IN experiments_NNS were_VBD from_IN passages_NNS three_CD
          to_TO six_CD ._.
        
        
          Reagents_NNP
          CPT_NNP (_( Sigma_NNP )_) was_VBD dissolved_VBN in_IN dimethyl_NN sulfoxide_NN
          (_( Sigma_NNP )_) ._. Aliquots_NNP of_IN stock_NN solution_NN (_( 10_CD mM_NN )_) were_VBD stored_VBN
          at_IN -_: 70_CD °_NN C_NNP and_CC diluted_VBN further_RB in_IN 1_CD %_NN FBS_NNP /_NN DMEM_NNP immediately_RB
          before_IN each_DT experiment_NN ._.
        
        
          Determining_VBG production_NN of_IN collagen_NN types_NNS I_PRP ,_, III_NNP ,_,
          and_CC VI_NNP and_CC of_IN elastin_NN
          Fibroblasts_NNP (_( 10_CD 4_CD cells_NNS /_NN well_RB )_) were_VBD seeded_VBN in_IN 96_CD -_: well_RB
          flat-bottom_JJ culture_NN plates_NNS (_( Costar_NNP ,_, Corning_NNP ,_, NY_NNP ,_, USA_NNP )_) and_CC
          treated_VBN with_IN CPT_NNP for_IN 24_CD h_NN ._. Deposition_NNP of_IN collagen_NN and_CC
          elastin_NN in_IN cell_NN and_CC matrix_NN layers_NNS was_VBD determined_VBN by_IN
          solid-phase_JJ ELISA_NNP with_IN antibodies_NNS against_IN goat_NN
          anti-collagen_JJ I_PRP (_( Chemicon_NNP )_) ,_, mouse_NN anti-collagen_JJ III_NNP
          (_( Telios_NNP )_) ,_, mouse_NN anti-collagen_JJ VI_NNP (_( Telios_NNP )_) ,_, or_CC mouse_NN
          anti-elastin_JJ (_( Sigma_NNP )_) ,_, at_IN dilutions_NNS recommended_VBN by_IN the_DT
          manufacturers_NNS ._.
          For_IN determination_NN of_IN newly_RB synthesized_JJ collagenous_JJ
          proteins_NNS ,_, fibroblasts_NNS were_VBD plated_JJ in_IN 12_CD -_: well_RB plates_NNS and_CC
          grown_VBN to_TO visual_JJ confluency_NN ._. The_DT medium_NN was_VBD changed_VBN to_TO
          serum-free_JJ medium_NN (_( 1_CD %_NN BSA_NNP /_NN DMEM_NNP )_) supplemented_JJ with_IN 50_CD
          μg_NN /_NN ml_NN of_IN ascorbic_JJ acid_NN for_IN 48_CD h_NN ._. Cells_NNP were_VBD treated_VBN with_IN
          CPT_NNP (_( from_IN 10_CD -_: 9_CD to_TO 10_CD -_: 6_CD mol_NN /_NN l_NN )_) in_IN the_DT presence_NN of_IN ascorbic_JJ
          acid_NN for_IN the_DT next_JJ 48_CD h_NN ._. 20_CD μCi_NN /_NN ml_NN of_IN [_NN 3_CD H_NNP ]_NN proline_NN (_( NEN_NNP ,_,
          Boston_NNP ,_, MA_NNP ,_, USA_NNP )_) was_VBD added_VBN during_IN the_DT last_JJ 24_CD h_NN of_IN
          incubation_NN with_IN CPT_NNP ._. Medium_NNP was_VBD harvested_VBN from_IN each_DT well_RB
          and_CC cells_NNS were_VBD trypsinized_JJ and_CC counted_VBN ._. Medium_NNP was_VBD
          dehydrated_JJ in_IN a_DT SpeedVac_NNP (_( Savant_NNP ,_, Holbrook_NNP ,_, NY_NNP ,_, USA_NNP )_) ._.
          Aliquots_NNP of_IN media_NNS normalized_JJ for_IN cell_NN number_NN were_VBD
          denatured_JJ by_IN boiling_VBG them_PRP in_IN the_DT SDS_NNP sample_NN buffer_NN and_CC
          were_VBD loaded_VBN on_IN 6_CD %_NN SDS-polyacrylamide_NNP gels_NNS ._. After_IN
          electrophoresis_NNS ,_, gels_NNS were_VBD enhanced_VBN by_IN immersion_NN in_IN
          2_CD ,_, 5_CD -_: diphenyloxazole_NN (_( PPO_NNP )_) and_CC visualized_JJ by_IN
          autoradiography_NN ._. The_DT intensity_NN of_IN collagenous_JJ protein_NN
          bands_NNS was_VBD quantitated_JJ using_VBG NIH-Image_NNP ._.
          The_DT effect_NN of_IN CPT_NNP on_IN total_JJ protein_NN synthesis_NN was_VBD
          studied_VBN using_VBG metabolic_JJ labeling_VBG with_IN [_NN 35_CD S_NNP ]_NN methionine_NN
          followed_VBN by_IN SDS-PAGE_NNP and_CC autoradiography_NN ._. Fibroblasts_NNP
          were_VBD grown_VBN to_TO confluence_NN in_IN 12_CD -_: well_RB plates_NNS ,_, starved_VBN for_IN
          48_CD h_NN ,_, and_CC treated_VBD with_IN CPT_NNP for_IN the_DT next_JJ 24_CD h_NN ._. After_IN CPT_NNP
          treatment_NN ,_, cells_NNS were_VBD incubated_JJ in_IN methionine-free_JJ medium_NN
          (_( Gibco_NNP )_) ,_, and_CC 10_CD μCi_NN /_NN ml_NN of_IN [_NN 35_CD S_NNP ]_NN methionine_NN (_( NEN_NNP )_) was_VBD
          added_VBN for_IN the_DT next_JJ 4_CD h_NN ._. Cells_NNP were_VBD solubilized_JJ in_IN RIPA_NNP
          buffer_NN (_( 50_CD mM_NN Tris-_NNP HCl_NNP [_NN pH_NN 8_CD ._. 0_CD ]_NN ,_, 150_CD mM_NN NaCl_NNP ,_, 0_CD ._. 02_CD %_NN sodium_NN
          azide_NN ,_, 0_CD ._. 1_CD %_NN SDS_NNP ,_, 100_CD μg_NN /_NN ml_NN phenylmethylsulfonyl_NN fluoride_NN ,_,
          1_CD %_NN NP-_NNP 40_CD ,_, 0_CD ._. 5_CD %_NN sodium_NN deoxycholate_NN ,_, and_CC 10_CD μM_NN sodium_NN
          orthovanadate_NN )_) ._. Protein_NNP concentrations_NNS were_VBD normalized_JJ
          for_IN cell_NN number_NN and_CC separated_VBN by_IN 6_CD %_NN SDS-PAGE_NNP ._.
        
        
          RNA_NNP preparation_NN and_CC northern_JJ blot_NN analysis_NN
          Fibroblasts_NNP were_VBD grown_VBN to_TO confluence_NN in_IN 10_CD %_NN FBS_NNP /_NN DMEM_NNP
          and_CC then_RB incubated_JJ in_IN serum-free_JJ medium_NN ._. The_DT cells_NNS were_VBD
          treated_VBN with_IN CPT_NNP at_IN concentrations_NNS from_IN 10_CD -_: 9_CD to_TO 10_CD
          -_: 6_CD mol_NN /_NN l_NN for_IN 24_CD h_NN ._. Total_NNP RNA_NNP was_VBD extracted_VBN and_CC analyzed_VBN by_IN
          northern_JJ blotting_VBG as_IN described_VBN previously_RB [_NN 23_CD ]_NN ._.
          Membranes_NNP were_VBD sequentially_RB hybridized_JJ with_IN radioactive_JJ
          probes_NNS for_IN α_NN 2_CD (_( I_NN )_) procollagen_NN and_CC GAPDH_NNP and_CC scanned_JJ with_IN a_DT
          PhosphorImager_NNP (_( Molecular_NNP Dynamics_NNP ,_, Inc_NNP ._. ,_, Sunnyvale_NNP ,_, CA_NNP )_)
          for_IN mRNA_NN quantitation_NN ._. SSc_NNP and_CC healthy_JJ dermal_NN fibroblast_NN
          RNA_NNP samples_NNS were_VBD analyzed_VBN together_RB ._.
        
        
          Assays_NNP of_IN transient_JJ transfection_NN and_CC
          chloramphenicol_NN acetyltransferase_NN
          Transient_NNP transfections_NNS of_IN normal_JJ dermal_NN fibroblasts_NNS
          were_VBD performed_VBN by_IN the_DT calcium_NN phosphate_NN /_NN DNA_NNP
          coprecipitation_NN technique_NN as_IN described_VBN previously_RB [_NN 24_CD ]_NN ._.
          Briefly_NNP ,_, the_DT cells_NNS were_VBD grown_VBN to_TO 70_CD %_NN confluence_NN in_IN 100_CD -_: mm_NN
          2_CD dishes_NNS in_IN 10_CD %_NN FBS_NNP /_NN DMEM_NNP and_CC were_VBD transfected_JJ with_IN 20_CD μg_NN
          of_IN plasmid_NN DNA_NNP containing_VBG the_DT -_: 353_CD fragment_NN of_IN the_DT
          collagen_NN α_NN 2_CD (_( I_NN )_) promoter_NN linked_VBN to_TO the_DT CAT_NNP reporter_NN gene_NN
          (_( -_: 353_CD COL_NNP 1_CD A_DT 2_CD /_NN CAT_NNP construct_VB )_) ._. The_DT pSV-β-galactosidase_JJ
          control_NN vector_NN (_( Promega_NNP )_) (_( 2_CD ._. 5_LS μg_NN )_) was_VBD co-transfected_JJ to_TO
          allow_VB normalization_NN for_IN transfection_NN efficiency_NN ._. The_DT day_NN
          after_IN transfection_NN ,_, cells_NNS were_VBD treated_VBN with_IN CPT_NNP (_( at_IN
          concentrations_NNS from_IN 10_CD -_: 12_CD to_TO 10_CD -_: 6_CD mol_NN /_NN l_NN )_) ,_, and_CC incubation_NN
          was_VBD continued_VBN for_IN the_DT next_JJ 24_CD h_NN ._. CAT_NNP assays_NNS were_VBD
          performed_VBN as_IN described_VBN previously_RB [_NN 24_CD ]_NN ._. Cell_NNP extracts_NNS
          normalized_JJ for_IN protein_NN concentration_NN were_VBD used_VBN to_TO measure_VB
          CAT_NNP activity_NN ,_, and_CC the_DT values_NNS obtained_VBN were_VBD corrected_VBN to_TO
          reflect_VB the_DT efficiency_NN of_IN transfection_NN relative_JJ to_TO the_DT
          co-transfected_JJ pSV-β-galactosidase_JJ vector_NN ._.
        
      
      
        Abbreviations_NNP
        anti-_NN Topo_NNP I_PRP =_SYM anti-topoisomerase_JJ I_PRP ;_: BSA_NNP =_SYM bovine_JJ serum_NN
        albumin_NN ;_: CAT_NNP =_SYM chloramphenicol_NN acetyltransferase_NN ;_: COL_NNP 1_CD A_DT 2_CD =_SYM
        type_NN α_NN 2_CD (_( I_NN )_) collagen_NN ;_: CPT_NNP =_SYM camptothecin_NN ;_: DMEM_NNP =_SYM Dulbecco_NNP 's_POS
        modified_VBN Eagle_NNP 's_POS medium_NN ;_: ELISA_NNP =_SYM enzyme-linked_JJ
        immunosorbent_NN assay_NN ;_: FBS_NNP =_SYM fetal_JJ bovine_JJ serum_NN ;_: GAPDH_NNP =_SYM
        glyceraldehyde-_NN 3_CD -_: phosphate_NN dehydrogenase_NN ;_: SEM_NNP =_SYM standard_JJ
        error_NN of_IN the_DT mean_NN ;_: SSc_NNP =_SYM systemic_JJ sclerosis_NN ;_: Topo_NNP I_PRP =_SYM
        topoisomerase_NN I_PRP ._.
      
    
  
